Cripps advises the shareholders of Bedfont Scientific on strategic investment from Keensight Capital

Cripps has advised the shareholders of Bedfont Scientific Limited on their sale of a majority stake in the business  to Keensight Capital, a leading European private equity firm specialising in healthcare and technology investments headquartered in Paris.

Founded in 1976 and based in Kent, longstanding Cripps’ client Bedfont Scientific designs and manufactures world-leading breath analysis and gas monitoring devices used across healthcare, diagnostics, and industry. Its flagship products, including the Smokerlyzer®, NObreath®, and Gastrolyzer®, are distributed in more than 70 countries worldwide.

This complex and substantial transaction marks a major milestone for Bedfont as it partners with Keensight Capital to accelerate global growth and innovation.

This transaction showcases Cripps’ ability to deliver integrated advice on sophisticated cross-border private equity deals, drawing together expertise from across its corporate, commercial, employment, and private wealth teams.

Jason Smith, Managing Director of Bedfont Scientific, commented: “Partnering with Keensight Capital marks an exciting milestone in Bedfont’s journey. Their expertise and global reach will help us accelerate our growth while continuing to innovate and deliver high-quality, life-enhancing medical technology. We’re grateful to the Cripps team for their support, professionalism, and clear guidance throughout this complex and fast moving process.”

John Kirkwood, Corporate Partner at Cripps, added: “It’s been a privilege to support the shareholders of Bedfont on this transformative deal. The transaction involved multiple workstreams across corporate, commercial, employment, and private wealth; a great example of Cripps’ ability to deliver integrated advice on complex cross-border transactions. We wish Jason and the team every success as they embark on this exciting next chapter with Keensight Capital.”

The Cripps team included John Kirkwood,  Victoria Symons, Freddie Pawlik, Lawrence Moran, Jack Broadley, Paul Maudgil, Kat Rogers, Aimee Mitchell, Emma Saunders and Paul Fairbairn.

Corporate finance advice to the sellers was provided by EC M&A, with Paul Hastings acting as legal advisers to Keensight Capital.